Astellas Pharma Inc. (4503.T)
JPY 1458.0
(1.32%)
JPY 1458.0
(1.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1973.61 Billion JPY | 108.06% |
| 2022 | 948.56 Billion JPY | 8.77% |
| 2021 | 872.08 Billion JPY | -1.74% |
| 2020 | 887.51 Billion JPY | -13.75% |
| 2019 | 1028.99 Billion JPY | 60.97% |
| 2018 | 639.25 Billion JPY | 8.36% |
| 2017 | 589.91 Billion JPY | 7.44% |
| 2016 | 549.09 Billion JPY | 1.66% |
| 2015 | 540.12 Billion JPY | 13.55% |
| 2014 | 475.66 Billion JPY | 23.67% |
| 2013 | 384.63 Billion JPY | 0.29% |
| 2012 | 383.53 Billion JPY | 0.27% |
| 2011 | 382.5 Billion JPY | 21.82% |
| 2010 | 313.99 Billion JPY | 1.21% |
| 2009 | 310.24 Billion JPY | -2.51% |
| 2008 | 318.22 Billion JPY | -3.07% |
| 2007 | 328.28 Billion JPY | -11.68% |
| 2006 | 371.7 Billion JPY | 1.23% |
| 2005 | 367.18 Billion JPY | 115.88% |
| 2004 | 170.09 Billion JPY | -2.72% |
| 2003 | 174.84 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2059.07 Billion JPY | 4.33% |
| 2024 Q2 | 1932.39 Billion JPY | -6.15% |
| 2023 Q4 | 1973.61 Billion JPY | 5.8% |
| 2023 FY | 1973.61 Billion JPY | 108.06% |
| 2023 Q3 | 1865.42 Billion JPY | -2.01% |
| 2023 Q2 | 1903.67 Billion JPY | 56.1% |
| 2023 Q1 | 1219.54 Billion JPY | 28.57% |
| 2022 FY | 948.56 Billion JPY | 8.77% |
| 2022 Q2 | 934.14 Billion JPY | -0.92% |
| 2022 Q3 | 943.52 Billion JPY | 1.0% |
| 2022 Q4 | 948.56 Billion JPY | 0.53% |
| 2022 Q1 | 942.79 Billion JPY | 8.11% |
| 2021 FY | 872.08 Billion JPY | -1.74% |
| 2021 Q1 | 866.58 Billion JPY | -2.36% |
| 2021 Q2 | 843.88 Billion JPY | -2.62% |
| 2021 Q3 | 889.95 Billion JPY | 5.46% |
| 2021 Q4 | 872.08 Billion JPY | -2.01% |
| 2020 FY | 887.51 Billion JPY | -13.75% |
| 2020 Q1 | 949.35 Billion JPY | -7.74% |
| 2020 Q4 | 887.51 Billion JPY | -4.39% |
| 2020 Q2 | 907.38 Billion JPY | -4.42% |
| 2020 Q3 | 928.23 Billion JPY | 2.3% |
| 2019 Q3 | 672.33 Billion JPY | -1.66% |
| 2019 FY | 1028.99 Billion JPY | 60.97% |
| 2019 Q2 | 683.68 Billion JPY | 0.94% |
| 2019 Q1 | 677.32 Billion JPY | 5.96% |
| 2019 Q4 | 1028.99 Billion JPY | 53.05% |
| 2018 Q1 | 590.63 Billion JPY | 0.12% |
| 2018 Q4 | 639.25 Billion JPY | 0.49% |
| 2018 Q3 | 636.11 Billion JPY | 5.28% |
| 2018 FY | 639.25 Billion JPY | 8.36% |
| 2018 Q2 | 604.24 Billion JPY | 2.3% |
| 2017 FY | 589.91 Billion JPY | 7.44% |
| 2017 Q1 | 581.58 Billion JPY | 5.92% |
| 2017 Q4 | 589.91 Billion JPY | 4.05% |
| 2017 Q3 | 566.96 Billion JPY | 4.07% |
| 2017 Q2 | 544.8 Billion JPY | -6.32% |
| 2016 Q2 | 485.92 Billion JPY | -3.41% |
| 2016 FY | 549.09 Billion JPY | 1.66% |
| 2016 Q4 | 549.09 Billion JPY | 1.61% |
| 2016 Q3 | 540.38 Billion JPY | 11.21% |
| 2016 Q1 | 503.09 Billion JPY | -6.86% |
| 2015 FY | 540.12 Billion JPY | 13.55% |
| 2015 Q2 | 447.58 Billion JPY | 0.31% |
| 2015 Q1 | 446.2 Billion JPY | -6.19% |
| 2015 Q3 | 465.5 Billion JPY | 4.0% |
| 2015 Q4 | 540.12 Billion JPY | 16.03% |
| 2014 Q2 | 420.15 Billion JPY | 8.73% |
| 2014 Q4 | 475.66 Billion JPY | -0.42% |
| 2014 Q3 | 477.66 Billion JPY | 13.69% |
| 2014 FY | 475.66 Billion JPY | 23.67% |
| 2014 Q1 | 386.42 Billion JPY | 0.47% |
| 2013 Q2 | 374.47 Billion JPY | -1.91% |
| 2013 Q3 | 404.8 Billion JPY | 8.1% |
| 2013 Q4 | 384.63 Billion JPY | -4.98% |
| 2013 FY | 384.63 Billion JPY | 0.29% |
| 2013 Q1 | 381.77 Billion JPY | -0.46% |
| 2012 Q4 | 383.53 Billion JPY | 4.55% |
| 2012 Q3 | 366.85 Billion JPY | 16.02% |
| 2012 Q2 | 316.19 Billion JPY | -10.18% |
| 2012 Q1 | 352.04 Billion JPY | -7.96% |
| 2012 FY | 383.53 Billion JPY | 0.27% |
| 2011 FY | 382.5 Billion JPY | 21.82% |
| 2011 Q2 | 346.78 Billion JPY | 0.17% |
| 2011 Q1 | 346.19 Billion JPY | 10.25% |
| 2011 Q4 | 382.5 Billion JPY | 4.74% |
| 2011 Q3 | 365.19 Billion JPY | 5.31% |
| 2010 Q4 | 313.99 Billion JPY | 5.29% |
| 2010 FY | 313.99 Billion JPY | 1.21% |
| 2010 Q3 | 298.2 Billion JPY | -11.31% |
| 2010 Q1 | 329.13 Billion JPY | 6.09% |
| 2010 Q2 | 336.23 Billion JPY | 2.16% |
| 2009 FY | 310.24 Billion JPY | -2.51% |
| 2009 Q2 | 307.65 Billion JPY | 0.0% |
| 2009 Q4 | 310.24 Billion JPY | 2.72% |
| 2009 Q3 | 302.01 Billion JPY | -1.83% |
| 2008 Q4 | 318.22 Billion JPY | 0.0% |
| 2008 FY | 318.22 Billion JPY | -3.07% |
| 2007 FY | 328.28 Billion JPY | -11.68% |
| 2006 FY | 371.7 Billion JPY | 1.23% |
| 2005 FY | 367.18 Billion JPY | 115.88% |
| 2004 FY | 170.09 Billion JPY | -2.72% |
| 2003 FY | 174.84 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 189.52 Billion JPY | -941.36% |
| Chugai Pharmaceutical Co., Ltd. | 306.96 Billion JPY | -542.943% |
| Ono Pharmaceutical Co., Ltd. | 115.06 Billion JPY | -1615.248% |
| Santen Pharmaceutical Co., Ltd. | 130.33 Billion JPY | -1414.322% |
| JCR Pharmaceuticals Co., Ltd. | 45.74 Billion JPY | -4214.009% |
| Daiichi Sankyo Company, Limited | 1763.11 Billion JPY | -11.939% |
| Otsuka Holdings Co., Ltd. | 924.92 Billion JPY | -113.382% |
| Perseus Proteomics Inc. | 295.46 Million JPY | -667869.472% |